Grace Therapeutics (GRCE) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies, aiming to improve clinical outcomes and patient compliance by reformulating existing pharmaceutical compounds.

• Pipeline includes three clinical-stage drug candidates: GTX-104 (IV nimodipine for aSAH), GTX-102 (oral-mucosal betamethasone spray for Ataxia Telangiectasia), and GTX-101 (topical bupivacaine spray for PHN).

• Prioritizing GTX-104 for development and commercialization, with GTX-102 and GTX-101 development deferred pending additional funding or partnerships.

• Holds over 40 granted and pending patents globally, with all three drug candidates eligible for orphan drug designation, offering potential regulatory and financial benefits.

• Management team includes experienced professionals in drug development, regulatory affairs, and commercialization, including a renowned neurosurgeon-scientist.

Financial performance and metrics

• Closed a private placement on February 11, 2025, raising approximately $13.8 million in net proceeds after fees and expenses.

• Common stock is listed on Nasdaq Capital Market under the symbol "GRCE"; last reported sale price was $2.54 per share on March 7, 2025.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; will receive net proceeds from any cash exercise of warrants.

• Proceeds from warrant exercises, if any, will be used for general corporate purposes, pre-commercial planning, commercial team build-out, and product launch if GTX-104 is approved.